The Immune System – Products
Product News
Lpath Granted Another Key U.S. Patent Related to iSONEP and ASONEP Drug Programs
New U.S. patent adds to four others received over last six months.
Product News
AnaSpec Introduces Industry’s First Zebrafish Specific Antibodies - Z-Fish™ Anti-Lysozyme
New product line of zebrafish specific antibodies to support the increasing needs of researchers.
Product News
Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens
U.S. patent and trademark office has issued an official notice of allowance for a new U.S. patent specific to the DPX-0907 therapeutic cancer vaccine.
Product News
Dynavax Reports Additional Positive Phase 1B Immunogenicity Data for Hepatitis B Therapy Candidate
The data for DV-601 has reported in a poster session Saturday, February 19 at the 21st Conference of the APASL 2011 in Bangkok, Thailand.
Product News
Synexus Support Vaccines Trials with Dedicated Team
Company has created vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase trials.
Product News
Dynavax Reports New Phase 1a and Phase 1b Data for Universal Flu Vaccine Candidate
The data is reported in Geneva, Switzerland at the world health organization 7th meeting on evaluation of pandemic influenza prototype vaccines.
Product News
CytoSorbents Corporation Broadens its Intellectual Property Portfolio
Company has announced the issuance of two additional U.S. patents, bringing its total patent portfolio to 29 issued patents.
Product News
Native Antigen Company Launched as Key Innovator to In-vitro Diagnostics Sector
New venture receives investment from the Mercia Fund and business angels to optimize diagnostic monitoring of infectious disease.
Product News
NimoGel™ Shows Promise at Preventing Delayed Complications of Sudden Brain Injury in a Preclinical Study
Edge Therapeutics plans Phase 2 clinical trial of NimoGel in 2012.
Product News
Cancer Research UK Identifies Novel Role for CD169+ Macrophages in Activating Invariant Natural Killer T Cells
Dr Patricia Barral and her colleagues study the cellular and molecular mechanisms controlling lymphocyte activation and eventual fate. Knowledge of these processes is invaluable not only in increasing our understanding of the causes of cancer but also in the treatment and prevention of infectious and autoimmune diseases.
Advertisement
